Shares in Roche jump on positive Polivy results

9 August 2021
roche_basel_large

Roche (ROG: SIX) has announced a successful trial outcome with Polivy (polatuzumab vedotin), an anti-CD79b antibody-drug conjugate (ADC) currently under investigation for the treatment of several types of non-Hodgkin's lymphoma (NHL) that the company is developing using Seagen (Nasdaq: SGEN) ADC technology.

The pivotal Phase III POLARIX trial investigating Polivy (polatuzumab vedotin) alongside MabThera/Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint.

"Achieving meaningful treatment effects in the front-line setting has the potential to be transformative"This endpoint was to demonstrate significantly improved and clinically-meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology